Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery

Digestive Diseases

Volumn 29, Issue 1, 2011, Pages 48-51

  Jansen, Peter L M ^a   Van Werven, Jochem ^b   Aarts, Edo ^c   Berends, Frits ^c   Janssen, Ignace ^c   Stoker, Jaap ^b   Schaap, Frank G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

Bariatric surgery; Bile salts; Fibroblast growth factor 19; Fibroblast growth factor 21

Indexed keywords

BILE SALT; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21;

CHOLEDOCHOJEJUNOSTOMY; CLINICAL ARTICLE; CONFERENCE PAPER; FOLLOW UP; HUMAN; INSULIN RESISTANCE; MORBID OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOMACH BYPASS; TREATMENT OUTCOME; WEIGHT REDUCTION;

BILE ACIDS AND SALTS; FIBROBLAST GROWTH FACTORS; GASTRIC BYPASS; HUMANS; OBESITY, MORBID;

EID: 79959509827     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000324128     Document Type: Conference Paper

References (10)

1. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA: Fibroblast growth factor 15 functions as anentero-hepaticsignal toreg ulate bile acid homeostasis. Cell Metab 2005; 2:217-225.
2. Bhatnagar S, Damron HA, Hillgartner FB: Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 2009; 284:10023-10033.
3. Shin DJ, Osborne TF: FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem 2009; 284:11110-11120.
4. Schreuder TC, Marsman HA, Lenicek M, van Werven JR, Nederveen AJ, Jansen PL, Schaap FG: The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010; 298:G440-G445.
5. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, Maratos-Flier E: Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59: 2781-2789.
6. Laferrère B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, Hart AB, Olivan B: Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007; 30:1709-1716. (Pubitemid 47036341)
7. Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, Badman MK, Maratos-Flier E, Mun EC, Pihlajamaki J, Auwerx J, Goldfine AB: Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity 2009; 17:1671-1677.
8. Nakatani H, Kasama K, Oshiro T, Watanabe M, Hirose H, Itoh H: Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism 2009; 58: 1400-1407.
9. Kohli R, Kirby M, Setchell KD, Jha P, Klustaitis K, Woollett LA, Pfluger PT, Balistreri WF, Tso P, Jandacek RJ, Woods SC, Heubi JE, Tschoep MH, D'Alessio DA, Shroyer NF, Seeley RJ: Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. Am J Physiol Gastrointest Liver Physiol 2010; 299:G652-G660.
10. Chau MD, Gao J, Yang Q, Wu Z, Gromada J: Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci USA 2010; 107:12553-12558.